Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | GRM5 | P41594 | 5/20 | 0.42 |
| ▸ | LMNA | P02545 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
| ▸ | ATR | Q13535 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | KMO | O15229 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19703381 | 0.90 | GRM5 (0.42) | CNR2ALDH1A1GRM5MCHR1ATR | |
| SCHEMBL19365309 | 0.90 | CNR2 (0.40) | CNR2ALDH1A1GRM5LMNAKDM4E | |
| SCHEMBL19706193 | 0.88 | CNR2 (0.40) | CNR2ALDH1A1GRM5MCHR1ATR | |
| SCHEMBL19365839 | 0.88 | CNR2 (0.51) | CNR2ALDH1A1GRM5ADORA2AADORA1 | |
| SCHEMBL19365577 | 0.88 | GRM5 (0.38) | CNR2ALDH1A1GRM5ATR | |
| SCHEMBL19670601 | 0.88 | POLB (0.41) | CNR2ALDH1A1MCHR1KMO | |
| SCHEMBL19364891 | 0.87 | MCHR1 (0.42) | CNR2ALDH1A1GRM5ADORA2AADORA1 | |
| SCHEMBL21841343 | 0.87 | KMO (0.41) | CNR2ALDH1A1MCHR1KMO | |
| SCHEMBL19364806 | 0.86 | CNR2 (0.43) | CNR2GRM5MCHR1ATRCNR1 | |
| SCHEMBL19365441 | 0.86 | ATR (0.48) | LMNAATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2020-03-17 | — | — | US | disclosed |
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2017-12-14 | — | — | US | disclosed |
| US-9765075-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | CNR2 2514/4885ALDH1A1 1726/4885GRM5 3471/4885 |
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | SIRT1, SIRT3, SIRT2 | CNR2 2514/4885ALDH1A1 1726/4885GRM5 3471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.